Summary of significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2018

Summary of significant accounting policies

Schedule of disaggregation of revenue

	Year Ended December 31,
	2018		2017		2016
	(in thousands)
Adzenys XR-ODT	$	26,631	$	20,377	$	3,803
Cotempla XR-ODT		19,014		1,590		—
Adzenys ER		(27)		—		—
Generic Tussionex		4,370		5,165		6,230
	$	49,988	$	27,132	$	10,033

Schedule of impacts to reported results due to new revenue standard

	Year Ended December, 31
	2017						2016
			New						New
			Revenue						Revenue
	As		Standard		As		As		Standard		As
Condensed consolidated statements of operations:	Reported		Adjustment		Adjusted		Reported		Adjustment		Adjusted
	(In thousands, except per share data)
Revenue: net product sales	$	25,018	$	2,114	$	27,132	$	9,154	$	879	$	10,033
Cost of goods sold		12,391		1,639		14,030		11,437		297		11,734
Gross profit (loss)		12,627		475		13,102		(2,283)		582		(1,701)
Net loss attributable to common stock		(66,247)		475		(65,772)		(83,333)		582		(82,751)
Net loss per share of common stock, basic and diluted		(2.68)		0.02		(2.66)		(5.19)		0.03		(5.16)

	December 31,2017
			New
			Revenue
	As		Standard		As
Condensed consolidated statements of balance sheet:	Reported		Adjustment		Adjusted
Inventories	$	13,459	$	(1,727)	$	11,732
Other current assets		5,093		(1,518)		3,575
Total current assets		82,640		(3,245)		79,395
Accrued expenses		10,570		10,374		20,944
Deferred revenue		14,676		(14,676)		—
Total current liabilities		37,602		(4,302)		33,300
Accumulated deficit		(266,365)		1,057		(265,308)
Total liabilities and stockholder's equity		107,353		(3,245)		104,108